CareDx, Inc. (CDNA) Stock AnalysisCDNACareDx, Inc.

CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

CareDx Inc is a good buy right now due to its strong financial performance, with a gross margin of 73.50% in Q2 2026 and a year-to-date price increase of 234.38%. The recent positive news about ARK Invest's interest in the biotech sector and the resolution of the transplant LCD positively impacts investor sentiment. However, the forward P/E ratio of 156.25 indicates high expectations, which could be a risk if growth does not meet these expectations.

3 analysts cover CDNA: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 18.00.